Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea · Delayed Price · Currency is KRW 5,560.00
-50.00 (-0.89%)
Sep 19, 2025, 9:40 AM KST
Hyundai Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 1,866 | 15,050 | 9,481 | 7,852 | 9,241 | 12,511 | Upgrade |
Other Revenue | -0 | -0 | -0 | - | - | - | Upgrade |
| 1,866 | 15,050 | 9,481 | 7,852 | 9,241 | 12,511 | Upgrade | |
Revenue Growth (YoY) | -89.23% | 58.73% | 20.76% | -15.04% | -26.14% | -58.41% | Upgrade |
Cost of Revenue | 1,788 | 3,258 | 4,490 | 5,140 | 6,012 | 6,104 | Upgrade |
Gross Profit | 78.31 | 11,792 | 4,992 | 2,712 | 3,229 | 6,408 | Upgrade |
Selling, General & Admin | 9,498 | 7,640 | 7,846 | 6,542 | 6,647 | 6,283 | Upgrade |
Research & Development | 5,465 | 3,055 | 6,401 | 16,456 | 4,763 | 1,968 | Upgrade |
Other Operating Expenses | 39.62 | 38.4 | 42.25 | 27.37 | 61.28 | 40.98 | Upgrade |
Operating Expenses | 15,297 | 11,001 | 14,795 | 29,023 | 12,519 | 10,838 | Upgrade |
Operating Income | -15,219 | 790.97 | -9,804 | -26,311 | -9,289 | -4,430 | Upgrade |
Interest Expense | -3,575 | -2,313 | -314.57 | -448.65 | -3,003 | -1,130 | Upgrade |
Interest & Investment Income | 889.57 | 210.7 | 669.19 | 536.69 | 291.71 | 195.91 | Upgrade |
Earnings From Equity Investments | -2,821 | -5,730 | - | 8,834 | 93.91 | 1,542 | Upgrade |
Currency Exchange Gain (Loss) | 49.81 | 3.73 | -68.67 | 48.15 | 20.39 | -102.31 | Upgrade |
Other Non Operating Income (Expenses) | 733.14 | 94.13 | -335.47 | -182.82 | -404.46 | -1,179 | Upgrade |
EBT Excluding Unusual Items | -19,942 | -6,944 | -9,853 | -17,524 | -12,291 | -5,104 | Upgrade |
Gain (Loss) on Sale of Investments | -137.44 | 14.05 | 123.67 | 910.99 | - | - | Upgrade |
Asset Writedown | - | - | -4,769 | - | -7,517 | -2,829 | Upgrade |
Pretax Income | -20,079 | -6,930 | -14,498 | -16,613 | -19,808 | -7,933 | Upgrade |
Income Tax Expense | 2.82 | - | 1.04 | -805.47 | 243.5 | 326.46 | Upgrade |
Earnings From Continuing Operations | -20,082 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade |
Net Income | -20,082 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade |
Net Income to Common | -20,082 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade |
Shares Outstanding (Basic) | 86 | 80 | 80 | 79 | 74 | 72 | Upgrade |
Shares Outstanding (Diluted) | 86 | 80 | 80 | 79 | 74 | 72 | Upgrade |
Shares Change (YoY) | 7.76% | 0.10% | 1.04% | 6.64% | 2.79% | 3.67% | Upgrade |
EPS (Basic) | -234.06 | -87.02 | -182.26 | -200.77 | -271.58 | -115.00 | Upgrade |
EPS (Diluted) | -234.06 | -87.02 | -182.50 | -201.00 | -271.58 | -115.00 | Upgrade |
Free Cash Flow | -6,838 | 2,087 | -6,548 | -18,087 | -4,285 | -17,702 | Upgrade |
Free Cash Flow Per Share | -79.69 | 26.21 | -82.31 | -229.72 | -58.04 | -246.46 | Upgrade |
Gross Margin | 4.20% | 78.35% | 52.65% | 34.53% | 34.95% | 51.22% | Upgrade |
Operating Margin | -815.61% | 5.26% | -103.40% | -335.10% | -100.52% | -35.41% | Upgrade |
Profit Margin | -1076.23% | -46.04% | -152.92% | -201.33% | -216.97% | -66.02% | Upgrade |
Free Cash Flow Margin | -366.44% | 13.87% | -69.06% | -230.36% | -46.37% | -141.49% | Upgrade |
EBITDA | -14,262 | 1,425 | -8,369 | -24,529 | -6,586 | -652.3 | Upgrade |
EBITDA Margin | - | 9.47% | -88.27% | - | -71.27% | -5.21% | Upgrade |
D&A For EBITDA | 957.21 | 633.82 | 1,435 | 1,782 | 2,703 | 3,778 | Upgrade |
EBIT | -15,219 | 790.97 | -9,804 | -26,311 | -9,289 | -4,430 | Upgrade |
EBIT Margin | - | 5.26% | -103.40% | - | -100.52% | -35.41% | Upgrade |
Advertising Expenses | - | 267.64 | 996.63 | 965.59 | 1,497 | 798.47 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.